A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

被引:40
作者
Wunderink, Richard G. [1 ]
Roquilly, Antoine [2 ]
Croce, Martin [3 ]
Gonzalez, Daniel Rodriguez [4 ]
Fujimi, Satoshi [5 ]
Butterton, Joan R. [6 ]
Broyde, Natasha [6 ]
Popejoy, Myra W. [6 ]
Kim, Jason Y. [6 ]
De Anda, Carisa [6 ]
机构
[1] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Pulm & Crit Care, Chicago, IL 60611 USA
[2] Univ Nantes, CHU Nantes, Serv Anesthesie Reanimat Chirurg, Hotel Dieu,Therapeut Antiinfect EA3826, F-44000 Nantes, France
[3] Reg One Hlth, Memphis, TN USA
[4] Nuevo Hosp Civil Guadalajara, Dept Intens Care, Guadalajara, Jalisco, Mexico
[5] Osaka Gen Med Ctr, Dept Trauma Crit Care & Emergency Med, Sumiyoshi Ku, Osaka, Japan
[6] Merck & Co Inc, Merck Res Labs, Kenilworth, NJ 07033 USA
关键词
gram-positive cocci; healthcare-associated bacterial pneumonia; Staphylococcal infections; ventilator-associated bacterial pneumonia; IN-VITRO ACTIVITY; SKIN-STRUCTURE INFECTIONS; NOSOCOMIAL PNEUMONIA; PRODRUG TR-701; VANCOMYCIN; MULTICENTER; PREVALENCE;
D O I
10.1093/cid/ciab032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are associated with high mortality rates. We evaluated the efficacy and safety of tedizolid (administered as tedizolid phosphate) for treatment of gram-positive ventilated HABP/VABP. Methods. In this randomized, noninferiority, double-blind, double-dummy, global phase 3 trial, patients were randomized 1:1 to receive intravenous tedizolid phosphate 200 mg once daily for 7 days or intravenous linezolid 600 mg every 12 hours for 10 days. Treatment was 14 days in patients with concurrent gram-positive bacteremia. The primary efficacy end points were day 28 all-cause mortality (ACM; noninferiority margin, 10%) and investigator-assessed clinical response at test of cure (TOC; noninferiority margin, 12.5%) in the intention-to-treat population. Results. Overall, 726 patients were randomized (tedizolid, n = 366; linezolid, n = 360). Baseline characteristics, including incidence of methicillin-resistant Staphylococcus aureus (31.3% overall), were well balanced. Tedizolid was noninferior to linezolid for day 28 ACM rate: 28.1% and 26.4%, respectively (difference, -1.8%; 95% confidence interval [CI]: -8.2 to 4.7). Noninferiority of tedizolid was not demonstrated for investigator-assessed clinical cure at TOC (tedizolid, 56.3% vs linezolid, 63.9%; difference, -7.6%; 97.5% CI: -15.7 to 0.5). In post hoc analyses, no single factor accounted for the difference in clinical response between treatment groups. Drug-related adverse events occurred in 8.1% and 11.9% of patients who received tedizolid and linezolid, respectively. Conclusions. Tedizolid was noninferior to linezolid for day 28 ACM in the treatment of gram-positive ventilated HABP/VABP. Noninferiority of tedizolid for investigator-assessed clinical response at TOC was not demonstrated. Both drugs were well tolerated.
引用
收藏
页码:E710 / E718
页数:9
相关论文
共 39 条
[1]  
Abdelraouf K, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01957-16, 10.1128/aac.01957-16]
[2]  
[Anonymous], 2019, SIVEXTRO TEDIZOLID P
[3]   Surveillance of tedizolid activity and resistance: In vitro susceptibility of Gram-positive pathogens collected over 5 years from the United States and Europe [J].
Bensaci, Mekki ;
Sahm, Daniel .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2017, 87 (02) :133-138
[4]  
CLSI, 2019, M100 PERFORMANCE STA
[5]   Short- vs Long-Duration Antibiotic Regimens for Ventilator-Associated Pneumonia A Systematic Review and Meta-analysis [J].
Dimopoulos, George ;
Poulakou, Garyphallia ;
Pneumatikos, Ioannis A. ;
Armaganidis, Apostolos ;
Kollef, Marin H. ;
Matthaiou, Dimitrios K. .
CHEST, 2013, 144 (06) :1759-1767
[6]  
European Center for Disease Prevention and Control, 2018, EUR CTR DIS PREV CON
[7]  
European Committee on Antimicrobial Susceptibility Testing (EUCAST), 2019, BREAKPOINT TABLES IN
[8]   On the interpretation of x(2) from contingency tables, and the calculation of P [J].
Fisher, RA .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY, 1922, 85 :87-94
[9]   Tedizolid Population Pharmacokinetics, Exposure Response, and Target Attainment [J].
Flanagan, S. ;
Passarell, J. ;
Lu, Q. ;
Fiedler-Kelly, J. ;
Ludwig, E. ;
Prokocimer, P. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) :6462-6470
[10]   Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers [J].
Housman, Seth T. ;
Pope, J. Samuel ;
Russomanno, John ;
Salerno, Edward ;
Shore, Eric ;
Kuti, Joseph L. ;
Nicolau, David P. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (05) :2627-2634